We found several blood biomarkers through computational secretome analyses, including aldo-keto reductase family 1 member B10 (AKR1B10), which reflected the progression of nonalcoholic fatty liver disease (NAFLD). The gene discussed is AKR1B10; the disease is metabolic dysfunction-associated steatotic liver disease.